Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort.

Autor: Asmar KE; Institut National de la Santé et de la Recherche Médicale UMR-1178, Equipe Dépressions, CESP, Le Kremlin Bicêtre F-94276, France; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France., Fève B; UPMC Univ Paris 06, Faculté de Médecine Saint-Antoine, Paris, France; INSERM UMR S938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire ICAN, Paris F-75012, France; Service d'Endocrinologie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, Paris F-75012, France., Colle R; Institut National de la Santé et de la Recherche Médicale UMR-1178, Equipe Dépressions, CESP, Le Kremlin Bicêtre F-94276, France; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France., Gressier F; Institut National de la Santé et de la Recherche Médicale UMR-1178, Equipe Dépressions, CESP, Le Kremlin Bicêtre F-94276, France; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France., Vievard A; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France., Trabado S; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Institut National de la Santé et de la Recherche Médicale UMR-S U1185, Le Kremlin Bicêtre F-94276, France; Service de Génétique moléculaire, Pharmacogénétique et Hormonologie, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France., Verstuyft C; Institut National de la Santé et de la Recherche Médicale UMR-1178, Equipe Dépressions, CESP, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France; Service de Génétique moléculaire, Pharmacogénétique et Hormonologie, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France; Institut National de la Santé et de la Recherche Médicale UMR_S 1184, Le Kremlin Bicêtre F-94276, France., Haffen E; Université de Franche-Comté, Faculté de Médecine de Franche-Comté, Service de Psychiatrie, CIC-1431 INSERM, EA 481 Neurosciences, CHU de Besançon et Service de Psychiatrie 25030, France., Polosan M; Univ. Grenoble Alpes, Inserm U836, Grenoble Institut de Neurosciences, CHU de Grenoble, Grenoble F-38000, France., Ferreri F; UPMC Univ Paris 06, Faculté de Médecine Saint-Antoine, Paris, France; Assistance Publique Hôpitaux de Paris, Hôpital Saint-Antoine, Service de Psychiatrie, 184 rue du Faubourg Saint-Antoine, Paris 75012, France., Falissard B; Institut National de la Santé et de la Recherche Médicale UMR-1178, Equipe Dépressions, CESP, Le Kremlin Bicêtre F-94276, France; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Hôpital Paul Brousse, Département de Biostatistiques, Villejuif F-94400, France., Chanson P; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Institut National de la Santé et de la Recherche Médicale UMR-S U1185, Le Kremlin Bicêtre F-94276, France., Becquemont L; Institut National de la Santé et de la Recherche Médicale UMR-1178, Equipe Dépressions, CESP, Le Kremlin Bicêtre F-94276, France; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France., Corruble E; Institut National de la Santé et de la Recherche Médicale UMR-1178, Equipe Dépressions, CESP, Le Kremlin Bicêtre F-94276, France; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre F-94276, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France. Electronic address: emmanuelle.corruble@aphp.fr.
Jazyk: angličtina
Zdroj: Journal of affective disorders [J Affect Disord] 2018 Dec 01; Vol. 241, pp. 22-28. Date of Electronic Publication: 2018 Jul 26.
DOI: 10.1016/j.jad.2018.07.059
Abstrakt: Background: Weight gain is a major side effect of antidepressant (AD) drugs. We assessed whether early weight gain is a predictor for long term weight gain in depressed patients treated with antidepressants.
Methods: In the six month prospective METADAP cohort, 260 non-overweight patients with a major depressive disorder (MDD), who have recently experienced a Major Depressive Episode (MDE) were assessed for early weight gain (>3%,>5%, and >7%) after one month of treatment, and for long term weight gain (>15% and >20%) after three and six months of treatment. ROC analysis was used to determine the predictive power of early weight gain.
Results: 12.4% (21/170) of patients became overweight after three months of treatment and 21.1% (26/123) were overweight after six months. Compared to non-early weight gainers, patients with early weight gain (>3%, >5% and >7%) were 11.3 (OR = 11.3, 95%CI: 4.6-27.6)], 9.9 (OR = 9.9, 95%CI: 3.6-26.9)] and 17.8 (OR = 17.8, 95%CI: 6.4-49.4)] times, respectively, more at risk of late weight gain (>15%). ROC analysis showed that early weight gain (>3%) after one month of treatment, was the best predictor of long term weight gain (≥15%) after three months [Area Under the Curve (AUC )= 87%] and six months of treatment (AUC = 88%) PERSPECTIVES: Given that our baseline sample consisted of strictly non-overweight patients, the 3% threshold for weight gain after one month should be used as an indicator to initiate early weight monitoring in depressed patients treated with antidepressants. High attrition rate remains a limitation in this cohort and other cohorts in psychiatric settings.
Disclosures: Bruno Falissard consults for and received lecture fees from for E. Lilly, BMS, Servier, Sanofi-Aventis, GlaxoSmithKline, HRA, Roche, Boeringer Ingelheim, Bayer, Almirall, Allergan, Stallergene, Genzyme, Pierre Fabre, Astra Zeneca, Novartis, Janssen, Astellas, Biotronik, Daiichi-Sankyo, Gilead, MSD, Lundbeck. Florence Gressier received lecture fees from for Servier, Lundbeck and a grant from Servier. Mircea Polosan consults for and received lecture fees from Astra-Zeneca, Bristol Myers Squibb, Lundbeck, Otsuka and Servier. Emmanuel Haffen consults for and received lecture fees from Astra-Zeneca, Bristol Myers Squibb, Pfizer, Lilly, Lundbeck, Otsuka, Sanofi-Aventis, Servier. Philippe Chanson has received unrestricted research and educational grants from Ipsen, Novartis, Novo-Nordisk, and Pfizer for the Department of Endocrinology and Reproductive Diseases, Hôpitaux Universitaires Paris-Sud and for INSERM U 693. He has served as investigator (principal or coordinator) for clinical trials funded by Novartis, Pfizer, Ipsen, Italopharmaco, Antisense, Prolor Biotech. He is member of Advisory Boards from Ipsen, Novartis, Viropharma. He gave lectures for Ipsen, Novartis, Pfizer, NovoNordisk. All the fees and honoraria were paid to his Institution. Bruno Falissard consults for and received lecture fees from NovoNordisk, MSD and Sanofi-Aventis. Laurent Bequemont has close family member working at Sanofi-Aventis, consults for Sanofi-Aventis, Pfizer, Servier and received lecture fees from Genzyme, GlaxoSmithKline, Bristol-Myers Squibb and Merck Sharp and Dohme. Khalil El Asmar, Séverine Trabado, Albane Vievard, Céline Verstuyft, Romain Colle and Emmanuelle Corruble have nothing to declare.
(Copyright © 2018. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: